The use of the HER1/HER2 inhibitor lapatinib in HER2-positive breast cancer, responsible for the amplification of the HER2 gene, is the best example for eliminating CSCs by targeting a particular cancer-specific genetic alteration [131]. This evidence concerns the gene EGFR and breast cancer.